The FDA recorded a supplement, dated 28 August 2026, to the biologics licence application for Yusimry (adalimumab-aqvh, BLA761216), an adalimumab biosimilar. The record lists Emerge Bioscience as the applicant and gives no detail of what the supplement changes.
Supplements to biosimilar licences commonly cover manufacturing, presentation or labelling changes. Without the content, it cannot be read as a new indication, a change in interchangeability status or a safety communication.
For rheumatologists, the practical relevance is limited to US prescribing. Its status with CDSCO in India is unknown.
- No change to adalimumab prescribing follows from this record.
- Check the FDA label if a presentation or device change affects your patients.
- Continue to record the biosimilar brand and batch for pharmacovigilance.
Why it matters
Biosimilar licence changes can alter devices or interchangeability, so they are worth recognising even when routine.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free